FMP

FMP

Enter

RAIN - Rain Therapeutics Inc.

Profile of Rain Therapeutics Inc.(RAIN), Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies

About

ceo

Mr. Avanish Vellanki M.B.A.

sector

Healthcare

industry

Biotechnology

website

https://www.rainthera.com

exchange

NASDAQ

Description

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

CIK

0001724979

ISIN

US75082Q1058

CUSIP

75082Q105

Address

8000 Jarvis Avenue

Phone

510 953 5559

Country

US

Employee

63

IPO Date

Apr 23, 2021

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep